Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia : Lesson Learned from a Prospective Observational Study
© 2023 S. Karger AG, Basel..
INTRODUCTION: Severe COVID-19 pneumonia can activate a cytokine storm. Hemoperfusion can reduce pro-inflammatory cytokines in sepsis but is still debated in the COVID-19 setting. Thus, we sought to investigate the benefits of HA-330 cytokine adsorption through clinical and laboratory outcomes.
METHODS: We conducted a single-center prospective observational study in adults with severe COVID-19 pneumonia admitted to the intensive care unit at Chiang Mai University Hospital (Chiang Mai, Thailand). Those with cytokine storms indicated by organ injury, including acute respiratory distress syndrome (ARDS), and high inflammatory markers were included. Patients treated with the HA-330 device were classified as a hemoperfusion group, while those without cytokine adsorption were classified as a control group. We compared the outcomes on day 7 after treatment and evaluated the factors associated with 60-day mortality.
RESULTS: A total of 112 patients were enrolled. Thirty-eight patients received hemoperfusion, while 74 patients did not. Baseline cytokine storm parameters were comparable. In univariate analysis, there was an improvement in clinical and laboratory effects from hemoperfusion therapy. In multivariate analysis, APACHE II score, SOFA score, PaO2/FiO2, the number of hemoperfusion sessions, the amount of blood purified, high-sensitivity C-reactive protein, and IL-6 were associated with mortality. Using at least 3 sessions of hemoperfusion could mitigate, the 60-day mortality (adjusted odds ratio 0.25, 95% confidence interval: 0.03-0.33, p = 0.001). By categorizing the amount of blood treated into 3 groups of <1 L/kg, 1-2 L/kg, and ≥2 L/kg, there was a linear dose-response association with survival, which was better in the higher volume purified (mortality 60% vs. 33.3% vs. 0%, respectively, p = 0.015).
CONCLUSIONS: The early initiation of HA-330 hemoperfusion could improve the severity score and laboratory outcomes of COVID-19 ARDS. The optimal dose of at least three sessions or the amount of blood purified greater than 1 L/kg was associated with a reduction in 60-day mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Blood purification - 53(2024), 1 vom: 09., Seite 10-22 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kusirisin, Prit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adsorption therapy |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 17.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000534914 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364102519 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364102519 | ||
| 003 | DE-627 | ||
| 005 | 20240117232007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000534914 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM364102519 | ||
| 035 | |a (NLM)37918373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kusirisin, Prit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia |b Lesson Learned from a Prospective Observational Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 17.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: Severe COVID-19 pneumonia can activate a cytokine storm. Hemoperfusion can reduce pro-inflammatory cytokines in sepsis but is still debated in the COVID-19 setting. Thus, we sought to investigate the benefits of HA-330 cytokine adsorption through clinical and laboratory outcomes | ||
| 520 | |a METHODS: We conducted a single-center prospective observational study in adults with severe COVID-19 pneumonia admitted to the intensive care unit at Chiang Mai University Hospital (Chiang Mai, Thailand). Those with cytokine storms indicated by organ injury, including acute respiratory distress syndrome (ARDS), and high inflammatory markers were included. Patients treated with the HA-330 device were classified as a hemoperfusion group, while those without cytokine adsorption were classified as a control group. We compared the outcomes on day 7 after treatment and evaluated the factors associated with 60-day mortality | ||
| 520 | |a RESULTS: A total of 112 patients were enrolled. Thirty-eight patients received hemoperfusion, while 74 patients did not. Baseline cytokine storm parameters were comparable. In univariate analysis, there was an improvement in clinical and laboratory effects from hemoperfusion therapy. In multivariate analysis, APACHE II score, SOFA score, PaO2/FiO2, the number of hemoperfusion sessions, the amount of blood purified, high-sensitivity C-reactive protein, and IL-6 were associated with mortality. Using at least 3 sessions of hemoperfusion could mitigate, the 60-day mortality (adjusted odds ratio 0.25, 95% confidence interval: 0.03-0.33, p = 0.001). By categorizing the amount of blood treated into 3 groups of <1 L/kg, 1-2 L/kg, and ≥2 L/kg, there was a linear dose-response association with survival, which was better in the higher volume purified (mortality 60% vs. 33.3% vs. 0%, respectively, p = 0.015) | ||
| 520 | |a CONCLUSIONS: The early initiation of HA-330 hemoperfusion could improve the severity score and laboratory outcomes of COVID-19 ARDS. The optimal dose of at least three sessions or the amount of blood purified greater than 1 L/kg was associated with a reduction in 60-day mortality | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adsorption therapy | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HA-330 | |
| 650 | 4 | |a Hemoperfusion | |
| 650 | 4 | |a Severe acute respiratory syndrome coronavirus 2 | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Noppakun, Kajohnsak |e verfasserin |4 aut | |
| 700 | 1 | |a Trongtrakul, Konlawij |e verfasserin |4 aut | |
| 700 | 1 | |a Vongsanim, Surachet |e verfasserin |4 aut | |
| 700 | 1 | |a Suteeka, Yuttitham |e verfasserin |4 aut | |
| 700 | 1 | |a Ophascharoensuk, Vuddhidej |e verfasserin |4 aut | |
| 700 | 1 | |a Pongsuwan, Karn |e verfasserin |4 aut | |
| 700 | 1 | |a Narongkiatikhun, Phoom |e verfasserin |4 aut | |
| 700 | 1 | |a Theerakittikul, Theerakorn |e verfasserin |4 aut | |
| 700 | 1 | |a Apaijai, Nattayaporn |e verfasserin |4 aut | |
| 700 | 1 | |a Chattipakorn, Siriporn C |e verfasserin |4 aut | |
| 700 | 1 | |a Chattipakorn, Nipon |e verfasserin |4 aut | |
| 700 | 1 | |a Srisawat, Nattachai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood purification |d 1993 |g 53(2024), 1 vom: 09., Seite 10-22 |w (DE-627)NLM012656127 |x 1421-9735 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2024 |g number:1 |g day:09 |g pages:10-22 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000534914 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2024 |e 1 |b 09 |h 10-22 | ||